BRIACELL THERAPEUTICS CORP. Increase (Decrease) in Accounts Payable
BRIACELL THERAPEUTICS CORP. (BCTX) reported Increase (Decrease) in Accounts Payable of -$1.11 million for the 9-month period ending 2026-04-30, per its 10-Q filed 2026-06-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-06-09
- BRIACELL THERAPEUTICS CORP. increase (decrease) in accounts payable for the quarter ending 2026-04-30 was $294.79K.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in accounts payable for the quarter ending 2026-01-31 was -$249.27K, a 132.40% decline year-over-year.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in accounts payable for the quarter ending 2025-10-31 was -$1.15M.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in accounts payable for the quarter ending 2025-07-31 was $4.50K, a 99.40% decline year-over-year.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in accounts payable for fiscal 2025 was -$3.89M, a 164.28% decline from fiscal 2024.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in accounts payable for fiscal 2024 was $6.05M, a 815.58% increase from fiscal 2023.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in accounts payable for fiscal 2023 was $660.46K, a 165.07% increase from fiscal 2022.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in accounts payable for fiscal 2022 was $249.16K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-04-30 | $294.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-09 | $45.52K derived: sum of 2 quarters · filed 2026-06-09 | -$1.11M 10-Q · filed 2026-06-09 | -$1.10M derived: sum of 4 quarters · filed 2026-06-09 |
| 2026-01-31 | -$249.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-10 | -$1.40M 10-Q · filed 2026-03-10 | -$1.40M derived: sum of 3 quarters · filed 2026-03-10 | -$3.12M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-10-31 | -$1.15M 10-Q · filed 2025-12-11 | -$1.15M derived: sum of 2 quarters · filed 2025-12-11 | -$2.87M derived: sum of 3 quarters · filed 2026-06-09 | -$2.11M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-07-31 | $4.50K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | -$1.72M derived: sum of 2 quarters · filed 2026-06-09 | -$950.26K derived: sum of 3 quarters · filed 2026-06-09 | -$3.89M 10-K · filed 2025-10-16 |
| 2025-04-30 | -$1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-09 | -$954.76K derived: sum of 2 quarters · filed 2026-06-09 | -$3.89M 10-Q · filed 2026-06-09 | -$3.14M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-01-31 | $769.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-10 | -$2.17M 10-Q · filed 2026-03-10 | -$1.42M derived: sum of 3 quarters · filed 2026-03-10 | $1.29M derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-10-31 | -$2.94M 10-Q · filed 2025-12-11 | -$2.19M derived: sum of 2 quarters · filed 2025-12-11 | $522.51K derived: sum of 3 quarters · filed 2025-12-11 | $3.80M derived: sum of 4 quarters · filed 2025-12-11 |
| 2024-07-31 | $748.38K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | $3.46M derived: sum of 2 quarters · filed 2025-10-16 | $6.74M derived: sum of 3 quarters · filed 2025-10-16 | $6.05M 10-K · filed 2025-10-16 |
| 2024-04-30 | $2.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-16 | $5.99M derived: sum of 2 quarters · filed 2025-06-16 | $5.30M 10-Q · filed 2025-06-16 | $5.43M derived: sum of 4 quarters · filed 2025-06-16 |
| 2024-01-31 | $3.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-03-12 | $2.59M 10-Q · filed 2025-03-12 | $2.72M derived: sum of 3 quarters · filed 2025-03-12 | $3.13M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-10-31 | -$689.82K 10-Q · filed 2024-12-16 | -$561.34K derived: sum of 2 quarters · filed 2024-12-16 | -$148.54K derived: sum of 3 quarters · filed 2024-12-16 | -$357.83K derived: sum of 4 quarters · filed 2024-12-16 |
| 2023-07-31 | $128.49K derived: 10-K 12 month − 10-Q 9 month · filed 2024-10-29 | $541.29K derived: sum of 2 quarters · filed 2024-10-29 | $331.99K derived: sum of 3 quarters · filed 2024-10-29 | $660.46K 10-K · filed 2024-10-29 |
| 2023-04-30 | $412.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-14 | $203.50K derived: sum of 2 quarters · filed 2024-03-18 | $531.97K 10-Q · filed 2023-06-14 | $774.19K derived: sum of 4 quarters · filed 2024-03-18 |
| 2023-01-31 | -$209.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-03-18 | $119.17K 10-Q · filed 2024-03-18 | $361.39K derived: sum of 3 quarters · filed 2024-03-18 | $54.19K derived: sum of 4 quarters · filed 2024-03-18 |
| 2022-10-31 | $328.47K 10-Q · filed 2023-12-14 | $570.69K derived: sum of 2 quarters · filed 2023-12-14 | $263.49K derived: sum of 3 quarters · filed 2023-12-14 | $548.30K derived: sum of 4 quarters · filed 2023-12-14 |
| 2022-07-31 | $242.22K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-25 | -$64.98K derived: sum of 2 quarters · filed 2023-10-25 | $219.83K derived: sum of 3 quarters · filed 2023-10-25 | $249.16K 10-K · filed 2023-10-25 |
| 2022-04-30 | -$307.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-14 | -$22.39K derived: sum of 2 quarters · filed 2023-06-14 | $6.95K 10-Q · filed 2023-06-14 | |
| 2022-01-31 | $284.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-03-16 | $314.14K 10-Q · filed 2023-03-16 | ||
| 2021-10-31 | $29.33K 10-Q · filed 2022-12-14 | |||
| 2021-07-31 | -$1.41M 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |